LIANG Ying. Afatinib as Second-Line Treatment of Patients with Advanced Squamous Cell Carcinoma of the Lung:The Interpretation of LUX-Lung 8[J]. Journal of Evidence-Based Medicine, 2015, 15(6): 321-322. DOI: 10.3969/j.issn.1671-5144.2015.06.001
|
Citation:
|
LIANG Ying. Afatinib as Second-Line Treatment of Patients with Advanced Squamous Cell Carcinoma of the Lung:The Interpretation of LUX-Lung 8[J]. Journal of Evidence-Based Medicine, 2015, 15(6): 321-322. DOI: 10.3969/j.issn.1671-5144.2015.06.001
|
LIANG Ying. Afatinib as Second-Line Treatment of Patients with Advanced Squamous Cell Carcinoma of the Lung:The Interpretation of LUX-Lung 8[J]. Journal of Evidence-Based Medicine, 2015, 15(6): 321-322. DOI: 10.3969/j.issn.1671-5144.2015.06.001
|
Citation:
|
LIANG Ying. Afatinib as Second-Line Treatment of Patients with Advanced Squamous Cell Carcinoma of the Lung:The Interpretation of LUX-Lung 8[J]. Journal of Evidence-Based Medicine, 2015, 15(6): 321-322. DOI: 10.3969/j.issn.1671-5144.2015.06.001
|
DownLoad: